

# Real World Testing Results

talkEHR



## Table of Contents

<b>GENERAL INFORMATION</b> .....	3
<b>STANDARDS UPDATES (INCLUDING STANDARDS VERSION ADVANCEMENT PROCESS (SVAP) AND UNITED STATES CORE DATA FOR INTEROPERABILITY (USCDI))</b> .....	3
<b>ATTESTATION</b> .....	4
<b>JUSTIFICATION FOR REAL WORLD TESTING APPROACH</b> .....	5
<b>SCHEDULE OF KEY MILESTONES</b> .....	5
<b>CARE SETTING(S)</b> .....	6
<b>SUMMARY OF TESTING AND KEY FINDINGS</b> .....	6
<b>§ 170.315(b)(3) Electronic prescribing</b> .....	7
<b>§ 170.315(b)(1) Transition of Care C-CDAs Functionality</b> .....	8
<b>§ 170.315(b)(2)-Clinical information reconciliation and incorporation</b> .....	9
<b>§ 170.315(b)(6) Batch Patient Data Export</b> .....	10
<b>§ 170.315(b)(7)(8)- Security tags - summary of care – send/received</b> .....	11
<b>§ 170.315(b)(9)- Care Plan</b> .....	12
<b>§170.315(C)(1)(2)(3) Clinical quality measures (CQMs) — record &amp; export, report and Calculate and Report</b> ....	13
<b>Associated Criteria: 170.315(e)(1)- Patient Portal Use</b> .....	14
<b>§ 170.315(f)(1) Transmission to immunization registries</b> .....	15
<b>§ 170.315(f)(2) Transmission to public health agencies – syndromic surveillance</b> .....	16
<b>§ 170.315(f)(4) Transmission to cancer registry</b> .....	17
<b>§170.315(f)(6) Transmission to Public health agencies(antimicrobial use and resistance reporting)</b> .....	18
<b>§170.315(f) (6) Transmission to public health agencies — health care surveys</b> .....	19
<b>§170.315(g)(7)-(g)(9)-Compliance of API Resource Query Support</b> .....	20
<b>§ 170.315(h)(1)—Direct Project</b> .....	21

This is the real world test report for CY 2022 for the talkEHR, certified EHR solution. It provides the real world test measurements and Metric/Outcomes that meet the intent and objectives of ONC’s Condition of Certification and Maintenance of Certification requirement for real world testing (§ 170.405 Real world testing) to evaluate compliance with the certification criteria and interoperability of exchanging electronic health information (EHI) within the care and practice setting which it is targeted for use.

**GENERAL INFORMATION**

Plan Report ID Number: [For ONC-Authorized Certification Body use only]

Developer Name: CareCloud, Inc

Product Name(s): talkEHR

Version Number(s): 1.0

Certified Health IT: MU3 2015 Edition

Product List (CHPL) ID(s): 15.04.04.2790.Talk.01.01.1.181217, 15.04.04.2790.Talk.01.01.1.181217

Developer Real World Testing Result Page URL: <https://www.talkehr.com/>

**STANDARDS UPDATES (INCLUDING STANDARDS VERSION ADVANCEMENT PROCESS (SVAP) AND UNITED STATES CORE DATA FOR INTEROPERABILITY (USCDI))**

Standard (and version)	NA
Updated certification criteria and associated product	NA
Health IT Module CHPL ID	NA
Method used for standard update	NA
Date of ONC-ACB notification	NA
Date of customer notification (SVAP only)	NA
Conformance measure	NA
USCDI-updated certification criteria (and USCDI version)	NA

## ATTESTATION


This Real World Testing report is complete with all required elements, including measures that address all certification criteria and care settings. All information in this plan is up to date and fully addresses the health IT developer's Real World Testing requirements.

Authorized Representative Name: Dr. Iram Fatima

Authorized Representative Email: iramfatima@carecloud.com

Authorized Representative Phone: (732) 336-1245

Authorized Representative Signature:

A handwritten signature in blue ink, appearing to be 'Iram Fatima', written over a faint blue circular stamp.

Date: 01/14/2023

## JUSTIFICATION FOR REAL WORLD TESTING APPROACH

We use the following testing methodologies/approaches.

### Reporting/Logging:

This methodology uses the logging or reporting capabilities of the EHR to examine functionality performed in the system. A typical example of this is the measure reporting done for the automate measure calculation required in 315(g)(2), but it can also be aspects of the audit log or customized reports from the EHR. This methodology often provides historical measurement reports which can be accessed at different times of the year and evaluate interoperability of EHR functionality, and it can serve as a benchmark for evaluating real world testing over multiple time intervals.

### Summative Testing:

Summative assessments will be used to measure which certified actions were performed at the conclusion of a given time period. These will be conducted by running reports and examining audit logs from within the certified health IT module to help demonstrate the frequency of actions within the given time frame, and where possible, whether those actions were successful or unsuccessful. High success rates should be an indicator of a successful implementation of a given certified capability in a real-world setting.

## SCHEDULE OF KEY MILESTONES

Key Milestone	Care Setting	Date/Timeframe	Status
1Q-2022: Begin communication with clients to ask for their support and participation in real-world testing. The goal is to have a sufficient number of clients committed for real world testing by the end of 1Q-2022	Ambulatory	1Q-2022	Met
2Q-2022. During the 2nd quarter of CY 2022, the real-world testing with clients will be scheduled and performed.	Ambulatory	2Q-2022	Met
Collect Result	Ambulatory	3Q-2022	Met
Submit Result to Real World Test Report	Ambulatory	January-2023	Met

**CARE SETTING(S)**

Care Setting	Justification
Ambulatory Care (We designed this measure to test general ambulatory sites that we support and target.)	Our EMR is designed for general/family practice, as well as certain subspecialties: <ul style="list-style-type: none"> <li>• Podiatry</li> <li>• Gynecology</li> <li>• Behavioral health</li> </ul> Providers will use our software exclusively in the Outpatient/ambulatory setting.

**SUMMARY OF TESTING AND KEY FINDINGS**

All of the certified criteria were available to all of the providers from the start of the year and users could utilize them per their needs. Also, the training meetings were conducted and real world testing training manuals were made available to all of the clients to facilitate real world testing.

Real world testing Logs, follow-ups with the providers were utilized to determine how often providers use the functions under test for the purposes of Real World testing including any challenges the practices may face.

For CY 2022 Real World Testing Measures, we have provided our results and findings. During our testing, we did not discover any errors or criteria non-conformities. Challenges encountered through the real-world testing were Low and no usage of the features implemented as a part of criteria requirements. Our signed attestation of compliance with the real world testing requirements is available on page 4 of this document.



## § 170.315(b)(3) Electronic prescribing

### Measurement Description

This measure is tracking and counting how many NewRx electronic prescriptions were created and successfully sent from the EHR Module to a pharmacy destination over the course of a given interval.

**Testing Methodology:** Reporting/Logging

**Relied Upon Software:** Surescripts eRx

**Testing Result:**

Practices Queried: 3

Metric and Outcomes
Reporting Interval: 90-days period (Oct 1, 2022 through Dec 30, 2022) 1) Number of prescriptions created: 3750 2) Number of prescriptions changed: 27 3) Number of prescriptions canceled: 352 4) Number of prescriptions renewed:1007

**Care Setting(S):** Internal Medicine, Podiatry, Gynecology and Behavioral health

Key Milestone	Care Setting	Date/Timeframe	Status
1Q-2022: Begin communication with clients to ask for their support and participation in real-world testing. The goal is to have a sufficient number of clients committed for real world testing by the end of 1Q-2022	Ambulatory	1Q-2022	Met
2Q-2022. During the 2nd quarter of CY 2022, the real-world testing with clients will be scheduled and performed.	Ambulatory	2Q-2022	Met
Collect Result	Ambulatory	3Q-2022	Met
Submit Result to Real World Test Report	Ambulatory	January -2023	Met

Electronic prescribing is widely used feature by all times of specialties. RWT testing results reveals our EHR Module functionality is working as expected.

**Challenges Encountered:** None

## § 170.315(b)(1) Transition of Care C-CDAs Functionality

### Measurement Description

This measure is tracking and counting how many C-CDAs are created and successfully sent from the EHR to a 3rd party during a transition of care event using Direct messaging during a transition of care event over a given interval.

**Testing Methodology:** Reporting/Logging

**RELIED UPON SOFTWARE EMR Direct (Version 2017)**

### Testing Result

Practices Queried: 3

Metric and Outcomes
Reporting Interval: 90-days period (Oct 1, 2022 through Dec 30, 2022) 1) Number of CCDAs created: 1350 2) Number of CCDAs sent via edge protocols:120

CARE SETTING(S): Internal Medicine, Podiatry, Gynecology and Behavioral health		
1Q-2022: Begin communication with clients to ask for their support and participation in real-world testing. The goal is to have a sufficient number of clients committed for real world testing by the end of 1Q-2022	Ambulatory	1Q-2022
2Q-2022. During the 2nd quarter of CY 2022, the real-world testing with clients will be scheduled and performed.	Ambulatory	2Q-2022
Collect Result	Ambulatory	3Q-2022
Submit Result to Real World Test Report	Ambulatory	January -2023

**Challenges Encountered:** None



## § 170.315(b)(2)-Clinical information reconciliation and incorporation

### Measurement Description

This modules enable to reconcile and incorporate information from C-CDAs formatted.

Testing Methodology: Reporting/Logging

### Testing Result:

Practices Queried: 3

#### Metric and Outcomes

Reporting Interval: 90-days period (Oct 1, 2022 through Dec 30, 2022)

- 1) Number of times a user reconciled medication list data from a received CCDA: 1430
- 2) Number of times a user reconciled allergies and intolerance list data from a received CCDA: 1430
- 3) Number of times a user reconciled problem list data from a received CCDA: 1430

CARE SETTING(S): Internal Medicine, Podiatry, Gynecology and Behavioral health

#### SCHEDULE OF KEY MILESTONES

Key Milestone	Care Setting	Date/Timeframe
1Q-2022: Begin communication with clients to ask for their support and participation in real-world testing. The goal is to have a sufficient number of clients committed for real world testing by the end of 1Q-2022	Ambulatory	1Q-2022
2Q-2022. During the 2nd quarter of CY 2022, the real-world testing with clients will be scheduled and performed.	Ambulatory	2Q-2022
Collect Result	Ambulatory	3Q-2022
Submit Result to Real World Test Report	Ambulatory	January-2023

#### Analysis and Key Finding

Our results reveal our EHR Module functionality is working as expected, but it also shows that this is not a feature our clients are regularly using in their day-to-day workflows.

**Challenges Encountered:** None

## § 170.315(b)(6) Batch Patient Data Export

### Measurement Description

Creates export summary documents formatted as a Continuity of Care (CCD) document template in accordance with the standard specified in § 170.205(a)(4) HL7 Implementation Guide for CDA® Release 2: Consolidated CDA Templates for Clinical Notes, DSTU Release 2.1, including at minimum the following data elements: Common Clinical Data Set (CCDS), Encounter diagnoses, Cognitive status, Functional status, Reason for referral, and referring or transitioning provider's name and office contact information

Testing Methodology: Reporting

### Testing Result:

Practices Queried: 3

#### Metric and Outcomes

Reporting Interval: 90-days period (Oct 1, 2022 through Dec 30, 2022)

- 1) Number of times a data export was performed for a patient: 824
- 2) Number of times a data export was performed for multiple patients in a single transaction: 2
- 3) Number of times a data export was performed for all patients in a single transaction: 0

CARE SETTING(S): Internal Medicine, Podiatry, Gynecology and Behavioral health

### SCHEDULE OF KEY MILESTONES

Key Milestone	Care Setting	Date/Timeframe
1Q-2022: Begin communication with clients to ask for their support and participation in real-world testing. The goal is to have a sufficient number of clients committed for real world testing by the end of 1Q-2022	Ambulatory	1Q-2022
2Q-2022. During the 2nd quarter of CY 2022, the real-world testing with clients will be scheduled and performed.	Ambulatory	2Q-2022
Collect Result	Ambulatory	3Q-2022
Submit Result to Real World Test Report	Ambulatory	January -2023

Challenges Encountered: None

## § 170.315(b)(7)(8)- Security tags - summary of care – send/received

### Measurement Description

This modules enable user to securely send summary of care(C-CDAs formatted)

**Testing Methodology:** Reporting/Logging

### Testing Result:

Practices Queried: 3

Metric and Outcomes
Reporting Interval: 90-days period (Oct 1, 2022 through Dec 30, 2022)
1) Number of CCDAs created: 1350
2) Number of CCDAs sent via edge protocols: 120
3) Number of CCDAs received via edge protocols: 20

CARE SETTING(S): Internal Medicine, Podiatry, Gynecology and Behavioral health

### SCHEDULE OF KEY MILESTONES

Key Milestone	Care Setting	Date/Timeframe
1Q-2022: Begin communication with clients to ask for their support and participation in real-world testing. The goal is to have a sufficient number of clients committed for real world testing by the end of 1Q-2022	Ambulatory	1Q-2022
2Q-2022. During the 2nd quarter of CY 2022, the real-world testing with clients will be scheduled and performed.	Ambulatory	2Q-2022
Collect Result	Ambulatory	3Q-2022
Submit Result to Real World Test Report	Ambulatory	January -2023

### Analysis and Key Finding

This measure will track number of C-CDA files send/receive electronically via HISP.

We utilized various reports and audit logs, including Automated Measure (315.g.2) reports, to determine our measure count

**Challenges Encountered:** None

## § 170.315(b)(9)- Care Plan

### Measurement Description

This modules enable user can record, change, access, create, and receive care plan information according to the Care Plan document template in the HL7 Implementation Guide for CDA® Release 2: Consolidated CDA Templates for Clinical Notes (US Realm), Draft Standard for Trial Use Release 2.1

Testing Methodology: Reporting/Logging

### Testing Result:

Practices Queried: 3

Metric and Outcomes
Reporting Interval: 90-days period (Oct 1, 2022 through Dec 30, 2022) 1) Number of CCDAs created: 1350 2) Number of CCDAs sent: 120

CARE SETTING(S): Internal Medicine, Podiatry, Gynecology and Behavioral health

### SCHEDULE OF KEY MILESTONES

Key Milestone	Care Setting	Date/Timeframe	Status
1Q-2022: Begin communication with clients to ask for their support and participation in real-world testing. The goal is to have a sufficient number of clients committed for real world testing by the end of 1Q-2022	Ambulatory	1Q-2022	Met
2Q-2022. During the 2nd quarter of CY 2022, the real-world testing with clients will be scheduled and performed.	Ambulatory	2Q-2022	Met
Collect Result	Ambulatory	3Q-2022	Met
Submit Result to Real World Test Report	Ambulatory	January -2023	Met

### Analysis and Key Finding

The measure produce numeric result of CCDA created and sent with EHR and shows that the EHR has conformance with certified functionality

**Challenges Encountered:** None



## §170.315(C)(1)(2)(3) Clinical quality measures (CQMs) — record & export, report and Calculate and Report

### Measurement Description

This measure is tracking and counting how many eCQM quality measures were successfully reported on by the EHR Module to CMS over the course of a given interval

CARE SETTING(S): Internal Medicine, Podiatry, Gynecology and Behavioral health

**Testing Result:** Practices Queried: 3, Reporting Interval: 90-days period (Oct 1, 2022 through Dec 30, 2022)

CQM Measures	Initial Population	Denominator	Numerator	Performance Rate
CMS 2 - Preventive Care and Screening: Screening for Depression and Follow-Up Plan	7405	7405	4832	72%
CMS 69 - Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan	6756	6756	4751	71%
CMS 122 - Diabetes: Hemoglobin A1c (HbA1c) Poor Control (> 9%)	1520	1520	1227	80%
CMS 130 - Colorectal Cancer Screening	2424	2424	903	37%
CMS 138 - Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention	4772	4772	3371	70%

Key Milestone	Care Setting	Date/Timeframe
1Q-2022: Begin communication with clients to ask for their support and participation in real-world testing. The goal is to have a sufficient number of clients committed for real world testing by the end of 1Q-2022	Ambulatory	1Q-2022
2Q-2022. During the 2nd quarter of CY 2022, the real-world testing with clients will be scheduled and performed.	Ambulatory	2Q-2022
Collect Result	Ambulatory	3Q-2022
Submit Result to Real World Test Report	Ambulatory	January -2023

### Analysis and Key Finding

Our results reveal our EHR Module functionality is working correctly as we no reported issues. Almost all of our clients use MIPS CQM measures for reporting MIPS Quality data but eCQM measures are not widely. Clients submit quality part of MIPS through claim based measure.

## Associated Criteria: 170.315(e)(1)- Patient Portal Use

### Measurement Description

This use case is tracking and counting how patients are given access to their portal account over the course of a given interval.

**Testing Methodology:** Reporting/Logging

### Testing Result:

Practices Queried: 3

#### Metric and Outcomes

90-days period:

The total count for the patients who log into their patient portal to view, download, or transmit their health data is 3320

**CARE SETTING(S):** Internal Medicine, Podiatry, Gynecology and Behavioral health

### SCHEDULE OF KEY MILESTONES

Key Milestone	Care Setting	Date/Timeframe
1Q-2022: Begin communication with clients to ask for their support and participation in real-world testing. The goal is to have a sufficient number of clients committed for real world testing by the end of 1Q-2022	Ambulatory	1Q-2022
2Q-2022. During the 2nd quarter of CY 2022, the real-world testing with clients will be scheduled and performed.	Ambulatory	2Q-2022
Collect Result	Ambulatory	3Q-2022
Submit Result to Real World Test Report	Ambulatory	January-2023

### Analysis and Key Finding

Testing results reveal our patient portal is extremely popular and widely used. Some practices had large number of patients accessing their portal but some reported patients accessing the portal.

**Challenges Encountered:** None



## § 170.315(f)(1) Transmission to immunization registries

### Measurement Description

This measure is tracking and counting how many immunization messages are created and successfully sent from the EHR Module to an IIS/immunization registry over the course of a given

**Testing Methodology:** Reporting/Logging

### Testing Result

interval.

Practices Queried: 3

The immunization information created is successfully transmitted to the immunization: 1451

### Analysis and Key Finding

For practices connected to an immunization registry, they were able to share data with the registry.

**Challenges Encountered:** None

## § 170.315(f)(2) Transmission to public health agencies – syndromic surveillance

### Measurement Description

This measure is tracking and counting how many the source syndromic surveillance content created and successfully sent from the EHR Module to registry over the course of a given interval.

Testing Methodology: Reporting/Logging

### Metric and Outcomes

Successful interoperability of syndromic surveillance content to an public health agencies: 0

### Testing Result:

Practices Queried: 3

The total count for capability to sending data to public health agencies is 0

### Analysis and Key Finding

Customers has not participated in this program because it requires a significant effort on the part of the customer to set up a connection to a test registry for Syndromic Surveillance testing, in order to reduce the burden on the customer, We have created the test customer instance in the production environment and point it to the NIST Syndromic Surveillance tool. This test reveals that the functionality is available in

### Challenges Encountered: None

the Real World in production and available for use as soon as a customer wants to use it.



## § 170.315(f)(4) Transmission to cancer registry

### Measurement Description

This measure is tracking and counting how many cancer case information are created and successfully sent from the EHR Module to registry over the course of a given interval.

Testing Methodology: Reporting/Logging

### Associated Certification Criteria

Successful interoperability of cancer case information to an Case registry

### Testing Result:

Practices Queried: 2

The total count for capability to sending data to public health agencies is 0

### Analysis and Key Finding

Customers has not participated in this program. talkEHR has entered 3 test that have cancer case information for electronic transmission in accordance with the HL7® IG for CDA Release 2: Reporting to Public Health Cancer Registries from Ambulatory Healthcare Providers, DSTU Release 1.1

The test result reveals that the talkEHR has the ability to create cancer case information and successfully sent to registry.

Challenges Encountered: None

## **§170.315(f)(6) Transmission to Public health agencies(antimicrobial use and resistance reporting)**

### **Measurement Description**

This measure is tracking that antimicrobial use and resistance reporting information is created and successfully sent from the EHR Module to registry over the course of a given interval.

Testing Methodology: Reporting/Logging

### Associated Certification Criteria

Successful interoperability of antimicrobial use and resistance reporting information to public health agencies.

### **Testing Result:**

Practices Queried: 2

The total count for capability to sending data to public health agencies is 0

### **Analysis and Key Finding**

Customers has not participated in this program. talkEHR has entered 3 tests that demonstrated Antimicrobial use and resistance reporting information in accordance with the following sections of the standard specified at § 170.205(r)(1) HL7 Implementation Guide for CDA® Release 2

**Challenges Encountered:** None

## §170.315(f) (6) Transmission to public health agencies — health care surveys

### Measurement Description

This measure is tracking that antimicrobial use and resistance reporting information is created and successfully sent from the EHR Module to registry over the course of a given interval.

Testing Methodology: Reporting/Logging

Associated Certification Criteria
Successful interoperability of health care surveys to public health agencies

### Testing Result:

Practices Queried: 2 ,

Successful interoperability of health care surveys to public health agencies: 0

### Analysis and Findings

Customers has not participated in this program. talkEHR has created 3 test patients and their representative data in the production system and also created Health Care survey documents and manually downloaded the Healthcare Survey documents.

talkEHR has used the NIST healthcare surveys Release 1.2 validator found here:

<https://cdavalidation.nist.gov/cdavalidation/muNHCS12.html> to confirm that the documents conform to expected standards.

Challenges Encountered: None

## §170.315(g)(7)-(g)(9)-Compliance of API Resource Query Support

### Measurement Description

This measure is tracking compliance of the EHR Module criteria functionality of support of API query of patient data resources.

Testing Methodology: Reporting/Logging

#### Metric and Outcomes

API is not actively being used by clients, we conducted real world testing for three test patient by verifying the functionality that is available in production is still compliant with ONC requirements. We have FHIR application using our APIs in production, our results indicate that it successfully connect with our server.

**Analysis and Key Findings:** This measure is applicable to all our targeted practice settings as the API capabilities work the same for all sites. Because this feature is not regularly used by our clients, we have tested this capability in production system by creating test patients. This method has verified that certified functionality is working for end users.

**Challenges Encountered:** None

## § 170.315(h)(1)—Direct Project

### Measurement Description

This measure is tracking and counting how many C-CDAs are created and successfully sent from the EHR to a 3rd party during a transition of care event using Direct messaging during a transition of care event over a given interval.

Testing Methodology: Reporting/Logging

### ASSOCIATED CERTIFICATION CRITERIA

#### Metric and Outcomes

Practices queried: 3  
 90 days period(90 Days (Oct 1, 2022 through December 31, 2022))  
 1) Number of Direct Messages sent 120

**RELIED UPON SOFTWARE:** EMR Direct (Version 2017)

### SCHEDULE OF KEY MILESTONES

Key Milestone	Care Setting	Date/Timeframe
1Q-2022: Begin communication with clients to ask for their support and participation in real-world testing. The goal is to have a sufficient number of clients committed for real world testing by the end of 1Q-2022	Ambulatory	1Q-2022
2Q-2022. During the 2nd quarter of CY 2022, the real-world testing with clients will be scheduled and performed.	Ambulatory	2Q-2022
Collect Result	Ambulatory	3Q-2022
Submit Result to Real World Test Report	Ambulatory	January -2023

### Analysis and Key Finding

This test result demonstrates that Direct Messages are exchanged with other systems which demonstrate that the certified capability is available and effective, regardless of the frequency it is used. However it is observed that there is moderate utilization by providers with a high success rate.

**Challenges Encountered:** None